Nature专题:第四大致命癌症大肠癌

2015-05-18 佚名 生物通

每年夺走近70万人的生命,大肠癌(Colorectal cancer,CRC)成为了仅次于肺癌、肺癌和胃癌的全球第四大最致命的癌症。大肠癌是一种现代疾病:在发达国家具有最高的发病率。但随着全球变得更为富有,越来越多的人转向西方饮食和生活方式,大肠癌的发病率还有可能增加。 最新一期(5月14日)的Nature杂志以“Outlook: Colorectal cancer

每年夺走近70万人的生命,大肠癌(Colorectal cancer,CRC)成为了仅次于肺癌、肺癌和胃癌的全球第四大最致命的癌症。大肠癌是一种现代疾病:在发达国家具有最高的发病率。但随着全球变得更为富有,越来越多的人转向西方饮食和生活方式,大肠癌的发病率还有可能增加。



最新一期(5月14日)的Nature杂志以“Outlook: Colorectal cancer ”为题,以九篇文章的形式专题介绍了大肠癌疾病的增长、早期筛查诊断、预防、前沿研究进展、治疗药物开发、与微生物组的关系等等相关内容。

取代结肠镜检查术的新型诊断技术

筛查结肠癌已成为了世界上许多地方的一项常规性检查。结肠镜检查术是通常用于检测早期结肠癌的一种最好的方法――但其是创伤性的。当前一些公司正在致力开发出新型的微创新技术来取代高创性的结肠镜检查术。

2014年年中,美国食品和药物管理局批准了一种叫做Cologuard的测试方法。这一粪便检测法结合了粪便免疫化学测试(FIT)和分析来检测特殊的遗传标记物――KRAS基因突变和与这一疾病相关的另两个基因的化学修饰。KRAS是一种与细胞分裂相关的基因,在大肠癌中这一基因常常发生突变。此外,德国Epigenomics公司研发出了一种叫做Epi proColon的血液测试方法,来检测SEPT9基因上一种特殊的化学标记。

鼓舞人心的前沿研究

2009年,Hubrecht研究所的Hans Clevers和Toshiro Sato开发出了一个研究发育及疾病的强大的新模型:衍生自成体干细胞的三维“类器官”,其复制出了肠壁细胞的一些结构。现在全球有100多家实验室在采用不同类型的类器官来研究癌症和其他的疾病。

而在本月Clevers再度宣布采用患者的肿瘤衍生出了一批大肠癌类器官,构建了首个癌症类器官生物银行,这些“类器官”培养物适用于大规模的药物筛查来检测与药物敏感性相关的一些遗传改变,为采用个体化治疗改善癌症患者的临床结局铺平了道路

另一项引人注目的研究是,约翰霍普金斯大学Sidney Kimmel综合癌症中心癌症生物学联合主任肿瘤学家Victor Velculescu,正在开发和改进的针对血流中肿瘤脱落DNA片段的测量和测序技术,他正尝试将血瓶变为一种“液体活检”,由此来鉴别肿瘤的特征并帮助监测治疗效应。

药物研发尚无突破性进展

尽管在过去的十年里一些新药将晚期大肠癌的平均生存期延长了一倍,患者往往还是在3年内死亡。临床前沿仍在缓步前行。

微生物组的贡献

在越来越多的疾病中,科学家们发现生活在我们体内的一些生物体起着大作用。异常的微生物组是引发大肠癌的原因还是结果仍然是未解之谜。这成为了这一疾病有待解决的几大基础问题之一。

参考文献:

1.Herb Brody.Colorectal cancer.Nature, May 13, 2015.doi:10.1038/521S1a

2.David Holmes.A disease of growth.Nature, May 13, 2015.doi:10.1038/521S2a

3.Cassandra Willyard.Screening: Early alert.Nature, May 13, 2015.doi:10.1038/521S4a

4.Lauren Gravitz.Prevention: Tending the gut.Nature, May 13, 2015.doi:10.1038/521S6a

5.Eric Bender.Q&A: Hans Clevers.Nature, May 13, 2015.doi:10.1038/521S15a

6.Eric Bender.Q&A: Victor Velculescu.May 13, 2015.doi:10.1038/521S9a

7.Megan Scudellari.Drug development: Mix and match.May 13, 2015.doi:10.1038/521S12a

8.Sarah DeWeerdt.Microbiome: Microbial mystery.May 13, 2015.doi:10.1038/521S10a

9.Shraddha Chakradhar.Colorectal cancer: 5 big questions.May 13, 2015.doi:10.1038/521S10a

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=59770, encodeId=d95e59e70b0, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59771, encodeId=1b0159e7184, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880656, encodeId=d7d6188065671, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 06 16:22:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707387, encodeId=5ea21e073874b, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Sat Dec 05 09:22:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30762, encodeId=63f830e6284, content=非常有用!很全面!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sun Jul 05 10:21:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24267, encodeId=2e9d2426e11, content=你以为找治愈方法那么容易哇!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b131625589, createdName=2015520llm, createdTime=Wed May 20 18:06:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24134, encodeId=ce2c241344d, content=额, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.86.239.**, createdTime=Tue May 19 16:04:00 CST 2015, time=2015-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24021, encodeId=9e7724021c4, content=赶紧找到治愈方法!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24023, encodeId=994e24023b1, content=可怕!, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=)]
    2016-01-26 doctording1

    这篇文章有一定深度

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=59770, encodeId=d95e59e70b0, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59771, encodeId=1b0159e7184, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880656, encodeId=d7d6188065671, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 06 16:22:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707387, encodeId=5ea21e073874b, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Sat Dec 05 09:22:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30762, encodeId=63f830e6284, content=非常有用!很全面!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sun Jul 05 10:21:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24267, encodeId=2e9d2426e11, content=你以为找治愈方法那么容易哇!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b131625589, createdName=2015520llm, createdTime=Wed May 20 18:06:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24134, encodeId=ce2c241344d, content=额, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.86.239.**, createdTime=Tue May 19 16:04:00 CST 2015, time=2015-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24021, encodeId=9e7724021c4, content=赶紧找到治愈方法!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24023, encodeId=994e24023b1, content=可怕!, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=)]
    2016-01-26 doctording1

    是一篇不错的文章

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=59770, encodeId=d95e59e70b0, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59771, encodeId=1b0159e7184, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880656, encodeId=d7d6188065671, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 06 16:22:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707387, encodeId=5ea21e073874b, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Sat Dec 05 09:22:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30762, encodeId=63f830e6284, content=非常有用!很全面!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sun Jul 05 10:21:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24267, encodeId=2e9d2426e11, content=你以为找治愈方法那么容易哇!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b131625589, createdName=2015520llm, createdTime=Wed May 20 18:06:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24134, encodeId=ce2c241344d, content=额, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.86.239.**, createdTime=Tue May 19 16:04:00 CST 2015, time=2015-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24021, encodeId=9e7724021c4, content=赶紧找到治愈方法!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24023, encodeId=994e24023b1, content=可怕!, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=)]
    2016-02-06 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=59770, encodeId=d95e59e70b0, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59771, encodeId=1b0159e7184, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880656, encodeId=d7d6188065671, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 06 16:22:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707387, encodeId=5ea21e073874b, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Sat Dec 05 09:22:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30762, encodeId=63f830e6284, content=非常有用!很全面!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sun Jul 05 10:21:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24267, encodeId=2e9d2426e11, content=你以为找治愈方法那么容易哇!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b131625589, createdName=2015520llm, createdTime=Wed May 20 18:06:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24134, encodeId=ce2c241344d, content=额, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.86.239.**, createdTime=Tue May 19 16:04:00 CST 2015, time=2015-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24021, encodeId=9e7724021c4, content=赶紧找到治愈方法!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24023, encodeId=994e24023b1, content=可怕!, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=59770, encodeId=d95e59e70b0, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59771, encodeId=1b0159e7184, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880656, encodeId=d7d6188065671, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 06 16:22:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707387, encodeId=5ea21e073874b, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Sat Dec 05 09:22:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30762, encodeId=63f830e6284, content=非常有用!很全面!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sun Jul 05 10:21:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24267, encodeId=2e9d2426e11, content=你以为找治愈方法那么容易哇!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b131625589, createdName=2015520llm, createdTime=Wed May 20 18:06:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24134, encodeId=ce2c241344d, content=额, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.86.239.**, createdTime=Tue May 19 16:04:00 CST 2015, time=2015-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24021, encodeId=9e7724021c4, content=赶紧找到治愈方法!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24023, encodeId=994e24023b1, content=可怕!, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=)]
    2015-07-05 Jianghuiqin

    非常有用!很全面!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=59770, encodeId=d95e59e70b0, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59771, encodeId=1b0159e7184, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880656, encodeId=d7d6188065671, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 06 16:22:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707387, encodeId=5ea21e073874b, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Sat Dec 05 09:22:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30762, encodeId=63f830e6284, content=非常有用!很全面!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sun Jul 05 10:21:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24267, encodeId=2e9d2426e11, content=你以为找治愈方法那么容易哇!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b131625589, createdName=2015520llm, createdTime=Wed May 20 18:06:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24134, encodeId=ce2c241344d, content=额, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.86.239.**, createdTime=Tue May 19 16:04:00 CST 2015, time=2015-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24021, encodeId=9e7724021c4, content=赶紧找到治愈方法!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24023, encodeId=994e24023b1, content=可怕!, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=)]
    2015-05-20 2015520llm

    你以为找治愈方法那么容易哇!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=59770, encodeId=d95e59e70b0, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59771, encodeId=1b0159e7184, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880656, encodeId=d7d6188065671, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 06 16:22:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707387, encodeId=5ea21e073874b, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Sat Dec 05 09:22:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30762, encodeId=63f830e6284, content=非常有用!很全面!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sun Jul 05 10:21:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24267, encodeId=2e9d2426e11, content=你以为找治愈方法那么容易哇!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b131625589, createdName=2015520llm, createdTime=Wed May 20 18:06:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24134, encodeId=ce2c241344d, content=额, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.86.239.**, createdTime=Tue May 19 16:04:00 CST 2015, time=2015-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24021, encodeId=9e7724021c4, content=赶紧找到治愈方法!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24023, encodeId=994e24023b1, content=可怕!, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=)]
    2015-05-19 112.86.239.**

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=59770, encodeId=d95e59e70b0, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59771, encodeId=1b0159e7184, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880656, encodeId=d7d6188065671, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 06 16:22:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707387, encodeId=5ea21e073874b, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Sat Dec 05 09:22:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30762, encodeId=63f830e6284, content=非常有用!很全面!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sun Jul 05 10:21:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24267, encodeId=2e9d2426e11, content=你以为找治愈方法那么容易哇!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b131625589, createdName=2015520llm, createdTime=Wed May 20 18:06:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24134, encodeId=ce2c241344d, content=额, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.86.239.**, createdTime=Tue May 19 16:04:00 CST 2015, time=2015-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24021, encodeId=9e7724021c4, content=赶紧找到治愈方法!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24023, encodeId=994e24023b1, content=可怕!, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=)]
    2015-05-18 yydlt

    赶紧找到治愈方法!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=59770, encodeId=d95e59e70b0, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59771, encodeId=1b0159e7184, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:52:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880656, encodeId=d7d6188065671, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 06 16:22:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707387, encodeId=5ea21e073874b, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Sat Dec 05 09:22:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30762, encodeId=63f830e6284, content=非常有用!很全面!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sun Jul 05 10:21:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24267, encodeId=2e9d2426e11, content=你以为找治愈方法那么容易哇!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b131625589, createdName=2015520llm, createdTime=Wed May 20 18:06:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24134, encodeId=ce2c241344d, content=额, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.86.239.**, createdTime=Tue May 19 16:04:00 CST 2015, time=2015-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24021, encodeId=9e7724021c4, content=赶紧找到治愈方法!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24023, encodeId=994e24023b1, content=可怕!, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yydlt, createdTime=Mon May 18 11:59:00 CST 2015, time=2015-05-18, status=1, ipAttribution=)]
    2015-05-18 yydlt

    可怕!

    0

相关资讯

JAMA Inter Med:素食与降低大肠癌风险相关

通过Seventh-Day Adventist在线发表在JAMA内科的一项研究,与非素食相比,吃素食与降低大肠癌风险相关。 根据这项研究的背景,大肠癌在美国是第二大癌症死亡原因。虽然对其筛选已高度重视,但通过降低危险因素的一级防御仍然是一个重要的目标。饮食因素已经被认定为是大肠癌的重要因素,例如红肉可增加大肠癌的风险,而富含膳食纤维的食物可降低风险。 研究结果显示,在77659名研究参与者中

Genetic Test Mol Bioma:华人研究,大肠癌有效预后基因

由脂肪细胞分泌的胶原样蛋白质即脂联素,脂联素由ADIPOQ基因生成。ADIPOQ基因的变异可能会2型糖尿病,心血管疾病,以及各种癌症的风险增加相关。 一项新的研究发现 ADIPOQ基因特定的变异与大肠癌风险或高或低相关,相关研究发表在Genetic Testing and Molecular Biomarkers杂志上。 哈尔滨医科大学Xin Guo等人探讨脂联素基因两个多态性和大肠癌之间

Cell Death&disease:大肠癌细胞坏死性药物疗法

大肠癌(Colorectal cancer)是致死率很高的主要癌症类型之一。目前用于治疗大肠癌的方法主要是药物治疗,比如5-FU,以及irinotecan。然而,临床上接受药物治疗的晚期大肠癌患者五年存活率不足10%。常规性的抗癌药物的主要作用机理是引起DNA的损伤以及细胞的死亡,包括线粒体介导的内源性细胞凋亡以及死亡受体介导的外源性细胞凋亡。在肿瘤恶化过程中,新产生的肿瘤细胞经常会发生遗传或

PNAS:非甾体抗炎药如何预防大肠癌

来自美国匹兹堡大学癌症研究所(UPCI)的研究人员在一项新研究中证实,阿司匹林和其他的非甾体抗炎药物(NSAIDs)能够通过在携带某一功能异常的突变基因的肠干细胞中诱导细胞自杀信号途径,来预防大肠癌形成。他们的研究结果发布在《美国国家科学院院刊》(PNAS)上。 高级研究员、匹兹堡医学院药理学与化学生物学系及匹兹堡大学癌症研究所副教授张林(Lin Zhang)博士说,科学家们很

木瓜种子含抑制大肠癌成分

日本一项新研究显示,木瓜种子中的一种成分能对大肠癌增殖的蛋白质起到抑制作用。这一发现将有助于开发出治疗和预防大肠癌的有效药物。 大肠细胞内异常蛋白质过剩堆积后,促进细胞增殖的基因就会变得活跃,最终导致癌细胞不断增殖。 冈山大学教授中村宜督率领的研究小组发现木瓜种子中含有的异硫氰酸苄酯能促使抑制癌细胞增殖的蛋白质与过剩堆积的异常蛋白质结合,从而能对促进癌细胞增殖的基因发挥抑制作用。

Oncogene:大肠癌的新型治疗靶点——CD58

大肠癌是一种十分常见的胃肠道癌症,近些年来,大肠癌的死亡率在中国位于癌症致死率的第三位,而且其发病率呈现逐年上升趋势。目前,越来越多的证据证明,肿瘤起始细胞不仅仅存在于大脑,乳腺,前列腺及胰腺等实体瘤中,这些细胞也存在于大肠癌中。实体瘤中的细胞有一种复杂的等级制度,其中,肿瘤起始细胞是一小群具有正常干细胞特性的肿瘤细胞,这些细胞可以自我更新,具有分化多潜能性和强大的致癌性。最近,有报道称,肿瘤起始